Tag: Juno Therapeutics

Home / Juno Therapeutics

Categories

Lisocabtagene maraleucel is approved by FDA for second-line treatment of large B-cell lymphoma

July 2022:  Lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc.) has been approved by the Food and Drug Administration for adult patients with large B-cell lymphoma (LBCL) who have refractor...
juno-therapeutics

Scan the code